The Leukemia & Lymphoma Society (LLS) and Celgene Corporation announced a partnership to identify and fund promising blood cancer research projects.
The collaboration will leverage LLS’s infrastructure for the identification and acceleration of innovative research at academic centers in priority research areas with significant unmet medical need. These projects will rapidly advance the scientific and medical understanding of the hematological malignances.
Likewise, Celgene and LLS will also work together through LLS’s Therapy Acceleration ProgramTM (TAP) to partner with biotechnology companies to speed the development of novel blood cancer treatments.
The Celgene partnership is the first for LLS’s new “Targets, Leads & Candidates ProgramTM” a novel approach to venture philanthropy partnerships with the pharmaceutical industry. These partnerships are critical for patients as they have the potential to bring together the most innovative academic science and transform it more quickly with pharmaceutical company resources into critically needed therapies.
“LLS is pleased to be collaborating with Celgene, a company known for innovation in research, to advance both basic academic research in the hematological malignancies, as well as the clinical-development stage projects in our TAP pipeline,” said LLS Chief Mission Officer Louis J. DeGennaro, Ph.D. “As always, our goal is getting new therapies to patients more quickly.”
“Celgene shares with LLS a deep commitment to high impact treatment for patients with leukemia and lymphoma,” said Thomas Daniel, M.D., Celgene President, Research and Early Development. “Through this relationship, we look forward to working with LLS to accelerate delivery of promising therapies to patients.”
Date: October 3, 2012
Source: Leukemia & Lymphoma Society
